Public Employees Retirement System of Ohio Increases Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Public Employees Retirement System of Ohio grew its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 21,458.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 91,192 shares of the company's stock after purchasing an additional 90,769 shares during the period. Public Employees Retirement System of Ohio owned about 0.20% of Pacira BioSciences worth $1,718,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Point72 Asset Management L.P. purchased a new position in shares of Pacira BioSciences during the 4th quarter valued at approximately $20,266,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Pacira BioSciences during the 4th quarter valued at approximately $8,558,000. Balyasny Asset Management L.P. purchased a new position in shares of Pacira BioSciences during the 4th quarter valued at approximately $8,180,000. Nuveen Asset Management LLC lifted its position in shares of Pacira BioSciences by 109.9% during the 4th quarter. Nuveen Asset Management LLC now owns 625,917 shares of the company's stock valued at $11,792,000 after buying an additional 327,754 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of Pacira BioSciences by 150.1% during the 4th quarter. Ameriprise Financial Inc. now owns 324,261 shares of the company's stock valued at $6,109,000 after buying an additional 194,597 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company's stock.

Pacira BioSciences Price Performance

PCRX stock traded down $0.77 during midday trading on Friday, reaching $25.97. The stock had a trading volume of 431,551 shares, compared to its average volume of 972,803. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $29.95. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -12.79 and a beta of 0.56. The company's fifty day simple moving average is $25.49 and its 200 day simple moving average is $23.26. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on PCRX shares. Barclays increased their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. HC Wainwright increased their target price on Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research report on Tuesday, April 8th. Finally, Needham & Company LLC decreased their price objective on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, Pacira BioSciences currently has a consensus rating of "Hold" and a consensus target price of $26.44.

Insiders Place Their Bets

In other Pacira BioSciences news, SVP Lauren Riker sold 5,578 shares of the firm's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total value of $146,199.38. Following the completion of the sale, the senior vice president now directly owns 59,564 shares of the company's stock, valued at $1,561,172.44. This trade represents a 8.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 6.40% of the company's stock.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.